Next-generation nanomedicine: Bridging tumor biology with individualized drug delivery

Introduction: Nanomedicine has made a significant impact in the field of oncology, with many nanosized systems reaching the market and clinical trials. These novel drug delivery systems often respond to biological triggers and temporarily target tissues, enhancing the therapeutic index of chemotherapeutics. Despite these advances, including stimuli-responsive and targeting ligand-decorated nanosystems, the therapeutic results have not yet fulfilled expectations. Objective: To explore the concept of smart nanodrug delivery systems designed for personalized oncology, focusing on how personalization can be integrated into the design, fabrication, and clinical translation of nanocarriers. Methods: A personalized approach encompasses tumor characterization and patient-specific profile analysis, resulting in predictive models that establish individual dosing regimens and predict therapeutic outcomes. Companion diagnostics allow monitoring of the tumor response to treatment and the modulation of dosing depending on therapeutic efficacy. Data were obtained from current literature describing tumor profiling, predictive modeling, and smart nanocarrier systems responding to biological or physical stimuli. Results: Smart nanocarriers integrate stimuli-responsive features and targeting moieties to exploit the tumor microenvironment. The application of these systems can be combined with predictive modeling and companion diagnostics to optimize therapy in real time. Preclinical investigations confirm that such systems enhance tumor targeting, improve drug bioavailability, and reduce systemic toxicity. The transition from design and fabrication to clinical translation involves validation of pharmacokinetics, biodistribution, and toxicity. Conclusion: The synergistic incorporation of multiple smart functionalities in nanocarriers for drug delivery in oncology provides a foundation for personalized medicine. Personalized dosing applications, predictive modeling, and companion diagnostics enable tailored therapeutic outcomes, reduced toxicity, and improved patient survival. The translation of smart nanocarrier platforms into clinical practice represents a crucial step toward personalized oncology.